Abstract
MDL 72,974 A, an irreversible inhibitor of monoamine oxidase type B (MAO-B),1 is currently in development for the treatment of Parkinson’s disease. This compound is highly specific and selective, with ED50 values for MAO-B and MAO-A of 0.18 and 8 mg/kg, acute treatment respectively, compared with 4.8 and 80 for L-deprenyl, the prototype MAO-B inhibitor.2 In addition, unlike L-Deprenyl, MDL 72,974 A is not metabolized in vivo to amphetamine or compounds having amphetamine-like effects,3 and has also been shown not to potentiate the effects of tyramine in healthy volunteers in doses up to 24 mg once per day.4
The European MDL 72,974 A Study Group (in alphabetical order): Investigators: J. Aasly, Trondheim, Norway; M. Baldy-Moulinier, Montpelier, France; P.J. Delwaide, Liége, Belgium; F. Durif, Chamaliéres, France; A.J. Lees (M.Merello), London, U.K., J.L. Montastruc, Toulouse, France; V. Myllylä (K. Sotaniemi) Oulu, Finland; J.D. Parkes (B. Summers) London, U.K.; W. Poewe, Berlin, Germany; P. Pollak, Grenoble, France; H. Teräväinen, Helsinki, Finland; J.M. Waiter, Strasbourg, France.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
M. Zreika, J.R. Fozard, M.W. Dudley, P. Bey, I.A. McDonald, and M.G. Palfreyman. MDL 72,974: a Potent and Selective Enzyme-Activated Irreversible Inhibitor of Monoamine Oxidase Type B with Potential for Use in Parkinson’s Disease, J. Neural. Transm. 243–254 (1989).
M.G. Palfreyman, I.A. MacDonald, M. Zreika, G. Cremer, K.D. Haegele, and P. Bey. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson’s Disease, J. Neural. Transm. 40: 101–111 (1993).
Moser P. The effects of L-deprenyl, MDL 72,974A and MDL 73,442A in rats trained to discriminate amphetamine from saline. Project report No. F-89–0112.
C. Hinze, M.K. Aschube, and J. Hardenberg. Pharmacodynamic of MDL 72,974A. Absence of effect on the pressure response to oral tyramine. Proceedings from the joint meeting of the 5th International Aminoxidase Workshop and 4th International Trace Amines Conferences (Galway), J. Neural. Transm. 41, in press, (1993).
W. Birkmayer, J. Knoll, P. Riederer, M.B.H. Youdim, V. Mars, and J. Marton. Increased Life Expectancy Resulting from Addition of L-Deprenyl to Madopar Treatment in Parkinson’s Disease: A Long-Term Study, J. Neural. Transm. 64 (2): 113–127 (1985).
U.K. Rinne. A New Approach to the Treatment of Parkinson’s Disease, Acta Neurol. Scand. (Suppl 95 ) 68: 7–144 (1983).
L.I. Golbe, A.N. Lieberman, M.D. Muenter, J.E. Ahlskog, G. Gopinathan, A.N. Neophytides, S.H.Foo, and R.C.Duvoisin. Deprenyl in the Treatment of Symptom Fluctuations in Advanced Parkinson’s Disease, Clin. Neuropharmacol. 11 (1): 45–55 (1988).
P. Riederer, M.B.H. Youdim, W.D. Rausch, W. Birkmayer, K. Jellinger, D. Seeman. On the Mode of Action of L-Deprenyl in the Human Central Nervous System, J. Neural. Transm. 43: 217–226 (1978).
J.Knoll. The Possible Mechanism of (-) Deprenyl in Parkinson’s Disease, J. Neural. Transm. 43: 177–198 (1978).
A.E. Lang, and S. Fahn. Assessment of Parkinson’s DisPace, in: “Quantification of Neurologic Deficit”, T.L. Munsat, ed, Boston, Butterworths: 285–309 (1989).
V. Myllyli, K. Sotaniemi, J. Aasly, O. Sjaastad, U. Rinne, T. McIntyre, and G. Cremer, An Open Multicentric Study of the Efficacy of MDL 72,974 A, a Monoamine Oxidase Type B (MAO-B) Inhibitor in Parkinson’s Disease. Advances in Neurology, Raven Press, Ltd. 60 (676–680) (1993).
Author information
Authors and Affiliations
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
McIntyre, T., Green, D., Cremer, G., Dow, M.M., The European MDL 72,974 A Study Group. (1995). MDL 72,974 A a Novel MAO-B Inhibitor: A European Multicentre Trial in Parkinson’s Disease as an Adjunct to Levodopa. In: Hanin, I., Yoshida, M., Fisher, A. (eds) Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology, vol 44. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9145-7_76
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9145-7_76
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9147-1
Online ISBN: 978-1-4757-9145-7
eBook Packages: Springer Book Archive